Skip to main content

Market Overview

UPDATE: Leerink Swann Downgrades Sanofi Based on Low Visibility


In a report published Friday, Leerink Swann analyst Seamus Fernandez downgraded Sanofi (NYSE: SNY) from Outperform to Market Perform and lowered the PT from €83 ($113.7142) to €80 ($109.6191) based on low visibility in the company's recovery.

Fernandez noted that this valuation does not include Sanofi's €3B ownership interest in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) or the potential repurchase of L'Oreal's 9% stake.

Leerink Swann commented that they continue to see long-term opportunity for products including alirocumab and dupilumab, but "we are skeptical that visibility on the base business, which includes substantial generic and tail product exposure, will improve materially during the next 12 months. This makes it increasingly difficult for us to recommend putting new money to work in SNY until consensus estimates better reflect this risk or substantial new pipeline opportunities emerge." The analyst further raised concern over the payor environment's ability to compete with other "faster-than-expected product launches."

Fernandez reduced his estimated EPS forecast for 2014 from €6.10 to €5.62 and sales estimate from €35,080 to €33,238.

Sanofi shares closed at $50.13 (€36.5993) on Thursday.


Related Articles (REGN + SNY)

View Comments and Join the Discussion!

Posted-In: Leerink Swann Seamus FernandezAnalyst Color Downgrades Analyst Ratings

Latest Ratings

TEXMorgan StanleyMaintains47.0
SYYMorgan StanleyMaintains81.0
SWKMorgan StanleyMaintains220.0
SUMMorgan StanleyMaintains31.0
SPGIMorgan StanleyMaintains421.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at